» Articles » PMID: 27453746

Outcome of Urinary Bladder Cancer After Combined Therapies

Overview
Journal J Med Life
Specialty General Medicine
Date 2016 Jul 26
PMID 27453746
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Urinary bladder cancer is the fourth most common cancer in men and the eighth in women, being an important public health issue.

Objective: to assess the outcome of patients with urinary bladder cancer treated in an oncologic center.

Methods: Medical files of 155 patients (132M/ 23F) with urinary bladder cancer treated between 2006 and 2012 were retrospectively analyzed. The median age at diagnosis was 65 years (range: 19-85 years). Disease free survival (DFS) for patients with complete tumor resection receiving adjuvant treatment and progression free survival (PFS) for patients with post-operative residual disease was estimated.

Results: Stage disease's distribution was: 50 patients (32.2%) stage II, 47 (30.3%) stage III, 58 (37.4%) stage IV. Radical cystectomy was performed in 56 patients (36.1%), while 99 patients (63.9%) underwent repeated transurethral resection of the urinary bladder tumor (TURBT). The postoperative treatment included multimodal therapy in 47 patients (30.3%) (chemotherapy and external beam radiation), external beam radiation alone in 57 patients (36.8%) and chemotherapy alone (methotrexate, vinblastine, doxorubicin, and cisplatin-MVAC or gemcitabine + platinum) in 51 patients (32.9%). After a median follow-up of 31 months (range: 3-79 months), 51 patients (32.9%) presented local recurrence, 32 patients (21%) distant recurrence (metastases), 10 patients (6.4%) both local and distant recurrence, and 62 patients (40%) were free of disease. The median duration until progression was of 27 months.

Discussion: Despite combined therapy approaches, urinary bladder carcinoma remains an aggressive disease, with high relapse rate. Earlier diagnosis and an aggressive radical surgery with the intention to cure (cystectomy), and adjuvant multimodal treatment (radiotherapy and chemotherapy) are needed for survival improvement.

Citing Articles

Expression and Clinical Significance of MMP-28 in Bladder Cancer.

Wang H, Wu J, Chen X, Zhang Q, Wei H, Wang H Technol Cancer Res Treat. 2020; 19:1533033820974017.

PMID: 33191847 PMC: 7672764. DOI: 10.1177/1533033820974017.


Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells.

Zangouei A, Rahimi H, Mojarrad M, Moghbeli M Diagn Pathol. 2020; 15(1):136.

PMID: 33183321 PMC: 7659041. DOI: 10.1186/s13000-020-01054-3.


[Expression of DNMT3b in human bladder cancer tissue and its correlation with clinical prognosis].

Cao Y, Xu K, Chen B, Wang Y, Li B, Li C Nan Fang Yi Ke Da Xue Xue Bao. 2020; 40(9):1295-1300.

PMID: 32990224 PMC: 7544589. DOI: 10.12122/j.issn.1673-4254.2020.09.11.


Association of human papilloma virus (HPV) infection with oncological outcomes in urothelial bladder cancer.

Ohadian Moghadam S, Mansori K, Nowroozi M, Afshar D, Abbasi B, Nowroozi A Infect Agent Cancer. 2020; 15:52.

PMID: 32874199 PMC: 7456036. DOI: 10.1186/s13027-020-00318-3.


Upregulation of miR-543-3p promotes growth and stem cell-like phenotype in bladder cancer by activating the Wnt/β-catenin signaling pathway.

Gao R, Chen X, Li Y, Yan X, Sun J, He Q Int J Clin Exp Pathol. 2020; 10(9):9418-9426.

PMID: 31966814 PMC: 6965893.


References
1.
Greven K, Spera J, Solin L, Morgan T, Hanks G . Local recurrence after cystectomy alone for bladder carcinoma. Cancer. 1992; 69(11):2767-70. DOI: 10.1002/1097-0142(19920601)69:11<2767::aid-cncr2820691123>3.0.co;2-#. View

2.
Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi F, De Lena M . Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol. 2000; 164(1):53-6. View

3.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

4.
Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, Weining C . Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol. 2005; 23(22):4963-74. DOI: 10.1200/JCO.2005.11.094. View

5.
Kim H, Steinberg G . The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. 2000; 164(3 Pt 1):627-32. DOI: 10.1097/00005392-200009010-00002. View